Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Bioenvision Charts. Click Here for more Bioenvision Charts.](/p.php?pid=staticchart&s=N%5EBIVN&p=8&t=15)
Bioenvision, Inc. (NasdaqGM:BIVN) will release fiscal 2007 first quarter
financial results at 7:00 a.m. Eastern Standard Time on November 9, 2006.
Christopher B. Wood, Chairman and CEO and David P. Luci, CFO and General
Counsel, will host an investment conference call beginning at 12:00 p.m.
Eastern Standard Time on November 9, 2006 to discuss these results and
to answer questions.
Conference Call Information:
Date: 11/9/06
Time: 12:00PM Eastern
Toll free (US & Canada): 866-585-6398
International: 416-849-9626
Web cast: www.bioenvision.com
A replay of the call and web cast will be available for 14 days.
Replay number (US & Canada): 866-245-6755
Replay number international: 416-915-1035
Replay passcode: 816197
Web cast replay: www.bioenvision.com
About Bioenvision
Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra®,
Modrenal® (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to initial
hormone therapy), and other products. Bioenvision is also developing
anti-infective technologies, including the OLIGON®
technology, an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus®,
an antimicrobial agent currently in clinical development for refractory
chronic hepatitis C infection. For more information on Bioenvision
please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking" statements
(as such term is defined in the Private Securities Litigation Reform Act
of 1995). Because these statements include risks and uncertainties,
actual results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to: risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's compounds
under development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for treatment of
disease; uncertainties inherent in the early stage of Bioenvision's
compounds under development; failure to successfully implement or
complete clinical trials; failure to receive marketing clearance from
regulatory agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that change
Bioenvision's business, structure or projections; the development of
competing products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in Bioenvision's
filings with the SEC. Bioenvision disclaims any obligation to update
these forward-looking statements.
Bioenvision, Inc. (NasdaqGM:BIVN) will release fiscal 2007 first
quarter financial results at 7:00 a.m. Eastern Standard Time on
November 9, 2006.
Christopher B. Wood, Chairman and CEO and David P. Luci, CFO and
General Counsel, will host an investment conference call beginning at
12:00 p.m. Eastern Standard Time on November 9, 2006 to discuss these
results and to answer questions.
-0-
*T
Conference Call Information:
Date: 11/9/06
Time: 12:00PM Eastern
Toll free (US & Canada): 866-585-6398
International: 416-849-9626
Web cast: www.bioenvision.com
A replay of the call and web cast will be available for 14 days.
Replay number (US & Canada): 866-245-6755
Replay number international: 416-915-1035
Replay passcode: 816197
Web cast replay: www.bioenvision.com
*T
About Bioenvision
Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies, including
the OLIGON(R) technology, an advanced biomaterial that has been
incorporated into various FDA approved medical devices and Suvus(R),
an antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.